Journal Article

Antibacterial susceptibility of a vancomycin-resistant <i> Staphylococcus aureus</i> strain isolated at the Hershey Medical Center

Bülent Bozdogan, Duygu Esel, Cynthia Whitener, Frederick A. Browne and Peter C. Appelbaum

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 52, issue 5, pages 864-868
Published in print November 2003 | ISSN: 0305-7453
Published online November 2003 | e-ISSN: 1460-2091 | DOI:
Antibacterial susceptibility of a vancomycin-resistant  Staphylococcus aureus strain isolated at the  Hershey Medical Center

Show Summary Details


Staphylococcus aureus strain HMC3 isolated at the Hershey Medical Center, was resistant to vancomycin (VRSA) through the presence of the vanA resistance gene; it also contained mecA, erm(A), erm(B), tet(K) and aac(6′)-aph(2″), conferring resistance to licensed β-lactams, macrolides, tetracycline and aminoglycosides. HMC3 also had alterations in GyrA and GrlB and was resistant to available quinolones. Experimental drugs with low MICs (<2 mg/L) for VRSA HMC3 included cephalosporins BAL9141 and RWJ-54428; glycopeptides oritavancin and dalbavancin; the lipopeptide daptomycin; the glycolipodepsipeptide ramoplanin; new fluoroquinolones WCK 771 A, WCK 1153, DK-507k and sitafloxacin; and the DNA nanobinder GS02-02. These agents were all bactericidal as were trimethoprim/sulfamethoxazole and teicoplanin (MIC 4 mg/L). Oxazolidinones linezolid and ranbezolid; the injectable streptogramin quinupristin/dalfopristin; DNA nanobinders GS2-10547 and GS02-104; peptide deformylase inhibitors NVP-PDF713 and GS02-12; tetracycline derivative tigecycline; the antifolate iclaprim; mupirocin and fusidic acid were all active in vitro but bacteriostatic.

Keywords: Keywords: S. aureus, VRSA, antimicrobial susceptibilities, mechanisms of resistance

Journal Article.  2597 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.